|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
CAMH Analysis & Videos »
CAMH: Bull or Bear?
CAMH breaks through $3.30 resistance
CAMH
|
|
|
Cambridge Heart up 2.4% after breaking through the $3.3 resistance level. Earnings reports are due in three weeks. At that time we should get some more positive news regarding the new sales and investment relationship with STJ as well as news on the sales ramp up.
|
Stock back on it's upward trend and ready to break through $3.30 resistance
CAMH
|
|
|
Now that the holiday is behind us, traders are back in force. CAMH had a nice move upward yesterday and is now just below the resistance level that has tested the last few runs.
There are still quite a few shorts out there but we have to take money from someone. All we need now is some news regarding one of the major insurers that have not yet required this test and we will be off to the races. Significant sales news will be a catalyst as well but we should not expect this until later in the year.
|
CAMH had a nice run. It will likely draw back a bit before moving higher
CAMH
|
|
|
As I have stated previously, CAMH is a great long play. We had a great run up the last few weeks but the stock has been pulling back while we wait for sales and manufacturing to ramp up. Revenue is projected to start it's climb upward in the 3rd and 4th calendar quarter.
We should see some upward momentum again when the two largest remaining hold outs (United Heathcare, Blue Cross) sign-up. As previously mentioned 50% of the insurers and Medicare have already signed on the dotted line. These will likely be sharp and quick moves up so if you are not on board you will probably miss < />< />...
|
Cambridge Heart Executing Final Stages of Strategy to Soar
CAMH
|
|
|
Cambridge Heart (CAMH) is in a unique position to capture virtually all market share in a new market. They have a developed a patented procedure and device to identify patients that are not at risk for Sudden Cardiac Death (SCD). This procedure and device has been approved by the FDA and European equivalent. Additionally, Medicare and half of the US insurers now mandate that this test be performed prior to being eligible for reimbursement for the implant of an ICD.
The market consists of 9000 US Cardiologist and an undetermined number of Electrophysiologist, Internists, and GP's....
|
People Bullish on CAMH
People Bearish on CAMH
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on CAMH |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Cambridge Heart Inc.
- Answers.com
